澳華內鏡(688212.SH):部分高級管理人員擬增持不超過620萬元公司股份
格隆匯9月22日丨澳華內鏡(688212.SH)發佈公吿,公司近日收到公司副總經理及董事會祕書施曉江、副總經理陳鵬、副總經理包寒晶、副總經理王希光的吿知函,基於對公司未來持續穩定發展的信心以及對公司股票長期投資價值的認可,擬自2024年9月23日起6個月內,通過上海證券交易所繫統允許的方式(包括但不限於集中競價交易、大宗交易等)增持公司股份,合計增持金額不低於370萬元(含,下同)且不超過620萬元(含,下同)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.